A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Jan 2017 Status changed from recruiting to discontinued.
- 01 Sep 2015 Planned number of patients changed from 600 to 300 as reported by ClinicalTrials.gov.
- 01 Sep 2015 Planned End Date changed from 1 Jan 2018 to 1 Jun 2017 as reported by ClinicalTrials.gov.